PURPOSE: The long-term outcome of node-positive breast cancer was analyzed to determine the risk of metastatic disease as a function of tumor size and number of positive nodes. METHODS: From 1927 to 1987, 501 women with node-positive breast cancer were treated at the University of Chicago Medical Center. Patients were treated with radical, extended radical, or modified radical mastectomy. Forty-eight patients received multiagent chemotherapy, and 118 were treated with hormonal therapy. The mean survival duration is 120 months, with a maximal follow-up time of 485 months (40 years). RESULTS: The number of nodes that contained metastatic disease and the pathologic size of the primary tumor were significant determinants of disease-free-survival (DFS) by multivariate analysis (P < .001). In patients with fewer than four positive nodes, tumor size was of prognostic importance, with small tumors more likely to be cured by local-regional therapy. The 20-year DFS rate for patients with one positive node was 69%; however, if the primary tumor was < or = 2 cm, the 20-year DFS rate was 81%, compared with 59% if the tumor was larger than 2 cm. Patients with two or three positive nodes had a 73% 20-year DFS rate if the tumor size was < or = 2 cm, compared with 53% 20-year DFS in patients with tumors larger than 2 cm. CONCLUSION: In patients with T1 lesions with less than four nodes positive, the long-term DFS rate is comparable to that for node-negative breast cancer of the same size. Four or more nodes positive is an indicator of likely systemic disease.
PURPOSE: The long-term outcome of node-positive breast cancer was analyzed to determine the risk of metastatic disease as a function of tumor size and number of positive nodes. METHODS: From 1927 to 1987, 501 women with node-positive breast cancer were treated at the University of Chicago Medical Center. Patients were treated with radical, extended radical, or modified radical mastectomy. Forty-eight patients received multiagent chemotherapy, and 118 were treated with hormonal therapy. The mean survival duration is 120 months, with a maximal follow-up time of 485 months (40 years). RESULTS: The number of nodes that contained metastatic disease and the pathologic size of the primary tumor were significant determinants of disease-free-survival (DFS) by multivariate analysis (P < .001). In patients with fewer than four positive nodes, tumor size was of prognostic importance, with small tumors more likely to be cured by local-regional therapy. The 20-year DFS rate for patients with one positive node was 69%; however, if the primary tumor was < or = 2 cm, the 20-year DFS rate was 81%, compared with 59% if the tumor was larger than 2 cm. Patients with two or three positive nodes had a 73% 20-year DFS rate if the tumor size was < or = 2 cm, compared with 53% 20-year DFS in patients with tumors larger than 2 cm. CONCLUSION: In patients with T1 lesions with less than four nodes positive, the long-term DFS rate is comparable to that for node-negative breast cancer of the same size. Four or more nodes positive is an indicator of likely systemic disease.
Authors: Allan W Silberman; Carie McVay; Jason S Cohen; Jack F Altura; Sandra Brackert; Gregory P Sarna; Daphne Palmer; Albert Ko; Leslie Memsic Journal: Ann Surg Date: 2004-07 Impact factor: 12.969
Authors: Yi Peng; Yirong Li; Lan Lin Gellert; Xuanyi Zou; Jun Wang; Baljit Singh; Ruliang Xu; Luis Chiriboga; Garrett Daniels; Ruimin Pan; David Y Zhang; Michael J Garabedian; Robert J Schneider; Zhengxin Wang; Peng Lee Journal: J Cell Mol Med Date: 2010-12 Impact factor: 5.310
Authors: Giacomo Montagna; Hersh V Gupta; Margaret Hannum; Kay See Tan; Jasme Lee; Joseph R Scarpa; George Plitas; Takeshi Irie; Patrick J McCormick; Gregory W Fischer; Monica Morrow; Joshua S Mincer Journal: Br J Anaesth Date: 2020-11-19 Impact factor: 9.166
Authors: G P Skliris; F Hubé; I Gheorghiu; M M Mutawe; C Penner; P H Watson; L C Murphy; E Leygue; Y Myal Journal: Histopathology Date: 2008-02 Impact factor: 5.087